Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 3/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60159 | 0.79 | TSHR (0.46) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL7326964 | 0.77 | MAPT (0.42) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL4372319 | 0.76 | MAPT (0.44) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL380136 | 0.71 | MAPT (0.48) | MAPTADORA2BXDHACHEGDA | |
| SCHEMBL541696 | 0.71 | MAPT (0.42) | MAPTADORA2BXDHACHEGDA | |
| SCHEMBL9386889 | 0.70 | MAPT (0.44) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL1150739 | 0.68 | XDH (0.47) | MAPTADORA2BXDHACHEGDA | |
| SCHEMBL3399435 | 0.68 | MAPT (0.48) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL31438586 | 0.68 | MAPT (0.48) | MAPTADORA2BXDHENPP1ACHE | |
| SCHEMBL5515639 | 0.68 | ADORA2B (0.49) | MAPTADORA2BXDHENPP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190373-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CARDIAC REMODELING AND HEART FAILURE | UNIVERSITY OF ROCHESTER (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2279009-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CARDIAC REMODELING AND HEART FAILURE | University Of Rochester (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009137465-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CARDIAC REMODELING AND HEART FAILURE | UNIVERSITY OF ROCHESTER (US) | 2009-11-12 | — | — | WO | disclosed |
| US-6812239-B2 | DETERMINING IF COMPOUND INHIBITS PHOSPHODIESTERASE 1C (PDE1C) IN PANCREATIC ISLET BETA-CELLS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-11-02 | — | — | US | disclosed |
| US-20020160939-A1 | Method of identification of inhibitors of PDE1C and methods of treatment of diabetes | MICHAELI TAMAR H (US) | 2002-10-31 | — | — | US | disclosed |
| US-6417208-B1 | PANCREATIC ISLET BETA-CELL CULTURE AND DETECTION OF INHIBITOR OF PHOSPHODIESTERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190373-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CARDIAC REMODELING AND HEART FAILURE | TNNI3, TNNT2, TNNC1 | MAPT 4308/4885ADORA2B 2021/4885XDH 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.